Current:Home > FinanceAn experimental Alzheimer's drug outperforms one just approved by the FDA -EliteFunds
An experimental Alzheimer's drug outperforms one just approved by the FDA
View
Date:2025-04-27 21:03:36
Patients in the early stages of Alzheimer's may soon have a new option to stave off the loss of memory and thinking.
In a study of more than 1,700 people, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%, scientists reported at the Alzheimer's Association International Conference in Amsterdam.
The result, published simultaneously in the journal JAMA, suggests that donanemab is at least as effective as the newly approved drug Leqembi (lecanemab), which was found to reduce progression by about 27%.
"This is the biggest effect that's ever been seen in an Alzheimer's trial for a disease-modifying drug," says Dr. Daniel Skrovonsky, director of research and development at Eli Lilly, which makes donanemab.
The company has submitted the results to the Food and Drug Administration and expects a decision by the end of the year.
But experts caution that donanemab is no cure, and that its benefit amounts to only about a seven-month delay in the loss of memory and thinking.
"I do think that will make a difference to people," says Dr. Reisa Sperling, who directs the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston. "But we have to do better."
Early treatment is key
Donanemab, like Leqembi, is a monoclonal antibody designed to remove a substance called beta-amyloid from the brain. Beta-amyloid tends to form sticky plaques in the brains of people with Alzheimer's.
The donanemab study focused on people whose brain scans showed plaques and other changes associated with early Alzheimer's. They had only mild cognitive symptoms.
Even within that group, though, people with more advanced disease saw less benefit from the drug.
"What we saw is that the ability to slow disease progression is strongest if you catch this disease earlier," Skrovonsky says.
The study also suggests that patients may not need monthly intravenous infusions of donanemab for life.
Patients were taken off the drug once the plaques in their brains were mostly gone, usually within a year. The plaques did not reappear during the 18-month study, and the benefit to memory and thinking continued.
That appears to give donanemab an edge over Leqembi, which requires ongoing treatment. But it's still not clear whether donanemab's benefits will persist for years after treatment ends.
"I imagine in the future we'll have this initiation phase where we knock down plaque and then we'll have maintenance therapy," Sperling says.
Both donanemab and Leqembi can cause dangerous swelling or bleeding in the brain.
In the donanemab study, brain scans revealed this side effect in about 25% of patients. About 6% had symptoms, like headache, nausea, and confusion. Three patients died.
A new era for Alzheimer's treatment?
The results with both donanemab and Leqembi provide strong evidence that removing amyloid from the brain can slow down Alzheimer's. That approach, known as the amyloid hypothesis, had been in doubt after dozens of other amyloid drugs failed to help patients.
One reason for the recent success is earlier treatment, Sperling says. Instead of treating patients who've already sustained significant brain damage from Alzheimer's, researchers have focused on people whose brains are still relatively healthy.
Another factor is the way researchers are approaching treatment, Sperling says.
"We've learned to be more aggressive with dosing," she says, which quickly reduces amyloid to very low levels in the brain.
But scientists still aren't sure which forms of amyloid offer the best target.
Single amyloid molecules appear to be harmless. But scientists have learned that when these molecules begin to clump together, they can take on forms that are toxic. Eventually, these clumps end up in plaques between brain cells.
"There's been a debate in our field for 30 years now about whether the plaques themselves are causing the problem," Sperling says. And the results with donanemab and leqembi are unlikely to end that debate.
Donanemab is designed to target plaques specifically. Leqembi is designed to target other forms of amyloid, though it also removes plaques.
Yet both drugs appear to slow down the loss of memory and thinking, in patients with early Alzheimer's.
A study Sperling is involved in could help answer the amyloid question by treating people who still have very little plaque in their brains.
"If we see benefit even at that stage," Sperling says, "one might argue it's not just plaque" eroding memory and thinking.
veryGood! (23146)
Related
- Off the Grid: Sally breaks down USA TODAY's daily crossword puzzle, Hi Hi!
- 50 love quotes to express how you feel: 'Where there is love there is life'
- Bachelor Alum Hannah Ann Sluss Reveals the Most Important Details of Her Wedding to Jake Funk
- New York City to pay $17.5 million to settle suit over forcing women to remove hijabs for mug shots
- Grammy nominee Teddy Swims on love, growth and embracing change
- Earthquakes happen all over the US, here's why they're different in the East
- Shin splints are one of the most common sports-related injuries. Here's how to get rid of them.
- Iowa-UConn women’s Final Four match was most-watched hoops game in ESPN history; 14.2M avg. viewers
- Trump suggestion that Egypt, Jordan absorb Palestinians from Gaza draws rejections, confusion
- Teen Moms Maci Bookout Reveals Where Her Co-Parenting Relationship With Ryan Edwards Stands Now
Ranking
- Senate begins final push to expand Social Security benefits for millions of people
- More than 65 years later, a college basketball championship team gets its White House moment
- First an earthquake, now an eclipse. Yankees to play ball on same day as another natural phenomenon
- The solar eclipse could deliver a $6 billion economic boom: The whole community is sold out
- Civic engagement nonprofits say democracy needs support in between big elections. Do funders agree?
- Kim Kardashian, Gwyneth Paltrow and more stars laud microdermabrasion. What is it?
- These Facts About Candace Cameron Bure Won't Fill Your House but They'll Expand Your Mind
- Caitlin Clark leads Iowa rally for 71-69 win over UConn in women’s Final Four. South Carolina awaits
Recommendation
Buckingham Palace staff under investigation for 'bar brawl'
Miami-area shootout leaves security guard and suspect dead, police officer and 6 others injured
WrestleMania 40 winners, highlights from night one: The Rock returns and much more
SWAT team responding to Arkansas shopping mall, police ask public to avoid the area
Megan Fox's ex Brian Austin Green tells Machine Gun Kelly to 'grow up'
More than 300 passengers tried to evade airport security in the last year, TSA says
Zambians Feel the Personal Consequences of Climate Change—and Dream of a Sustainable Future
Old Navy’s Sale Is Heating Up With up to 70% off and Deals Starting at Under $10